Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Elevation Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on nebulized solutions for chronic obstructive pulmonary disease and asthma, closed a $30M Series B financing. Participants include Novo Ventures, Canaan Partners, TPG Biotech, Care Capital and Mesa Verde Venture Partners.

Uptake Medical (Tustin, CA) a development-stage medical device company focused on non-surgical treatments for severe emphysema, COPD and lung diseases, closed a $35M Series C financing. Participants include Affinity Capital, Arboretum Ventures, GBS Venture Partners, Onset Ventures, Prism VentureWorks, Maverick Captial and WRF Capital.

Pulmatirx (Lexington, MA) a clinical-stage biotech company focused on COPD and astham, closed a $14M Series B financing. Participants include Polaris Venture Partners, 5AM Ventures, Arch Venture Partners and Novartis Venture Fund. Thanx for your patience as we catch-up.

Elevation Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on aerosol therapies for respiratory disease and COPD, closed a $17M Series A financing. Participants include Canaan Partners, Care Capital, TPG Biotech and Mesa Verde Venture Partners.

Pearl Therapeutics (Redwood City, CA) a clinical-stage small molecule company focused on combination therapy for chronic obstructive pulmonary disease, closed a $69M Series C financing. Participants include Vatera Healthcare Partners, Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

N30 Pharma (Boulder, CO) a preclinical-stage biopharmaceutical company focused on small molecules inhibting GSNOR for the potential treatment of asthma, COPD, inflammatory bowel disease and heart failure, closed a $10M Series B financing. Participants include Deerfield Management, Tiger Management, Bridger Capital and Swift Current Partners.

Funxional Therapeutics (United Kingdom) a clinical-stage small molecule company focused on asthma, COPD and other respiratory disorders, closed a $12.2M Series B financing. Participants include Ventech, Index Ventures and Novo Ventures.

Pearl Therapeutics (Redwood City, CA) a clinical-stage pharma company focused on metered dose inhaler products for the treatment of COPD and asthma, closed a $15M Series C financing. Participants include Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

Elevation Pharmaceuticals (San Diego, CA) a preclinical-stage biopharmaceutical company focused on developing improved inhaled drug therapies for COPD , closed a $30M Series A financing. Participants include Canaan Partners, TPG Growth, Care Capital and Mesa Verde Venture Partners.

Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture […]

Inspired Technologies (North Huntingdon, PA) a commercial-stage medical device company focused on auto-titration of oxygen delivery for COPD patients, closed a $5.4M Series B financing. Participants have included Birchmere Ventures, Cardinal Partners, Draper Triangle Ventures and Innovation Ventures.

Aerovance (Berkeley, CA) a clinical-stage company focused on respiratory and allergic diseases, closed a $38M Series C financing. Participants include ProQuest Investments, BB Biotech Ventures, Apax Partners, Clarus Ventures, Alta Partners, Lehman Brothers, NGN Capital and Burrill & Co.

Mpex Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on antibiotic therapy in patients with cystic fibrosis and COPD, closed a $27.5M Series D financing. Participants include Investor Growth Capital, SV Life Sciences, HBM BioVentures, Aberdare Ventures and Adams Street Partners.

« Previous Entries  Next Page »

to top of page...